What is ROE for Teleflex Incorporated in the second quarter 2025?
Teleflex Incorporated achieved a return on average equity (ROE) of 4.49 % in its second quarter 2025, which is below Teleflex Incorporated's average return on equity, which stands at 9.17%.

ROE has advanced compared to 3.43% in the first quarter 2025, due to net income growth.

Within the Medical Equipment & Supplies industry 44 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 1733, from total ROE ranking in the first quarter 2025 at 1870.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Return On Equity	(Jun 29 2025) II. Quarter	(Mar 30 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 29 2024) III. Quarter	(Jun 30 2024) II. Quarter
Y / Y Equity Change	-6.93 %	-9.06 %	-3.67 %	3.89 %	-
Y / Y Net Income Change	53.15 %	521.37 %	-	-19.06 %	-28.11 %
Net Income (TTM) in Millions	192	149	70	237	264
Return On Equity (TTM)	4.49 %	3.43 %	1.56 %	5.28 %	5.92 %
TFX's Total Ranking	# 1733	# 1870	# 1981	# 763	# 1372
Equity (TTM) in Millions	4,243	4,095	4,278	4,482	4,559
Seq. Equity Change	3.61 %	-4.28 %	-4.54 %	-1.69 %	1.23 %
Seq. Net Income Change	29.03 %	-	-	38.69 %	423.5 %

Back to TFX Management Effectiveness >> TFX's 5 Years Annual ROE >> Compare TFX ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 45
Sector	# 144
Overall	# 1733

Return On Equity Statistics
High	Average	Low
19.07 %	9.17 %	-1.73 %
(Mar 29 2020)		(Mar 28 2021)

TFX Annual Return On Equity	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021	(Dec 31 2020) 2020
Total Equity in Millions	4,278	4,441	4,022	3,755	3,336
Y / Y Equity Change	-3.67 %	10.42 %	7.12 %	12.54 %	11.99 %
Net Income in Millions	70	356	363	485	335
Y / Y Net Income Change	-80.45 %	-1.88 %	-25.18 %	44.75 %	-27.34 %
Return On Equity	1.63 %	8.02 %	9.03 %	12.93 %	10.05 %

Back to TFX Management Effectiveness >> TFX's 5 Years Annual ROE >> Compare TFX ROE to its Competitors

Annual Roe Comment

In 2024 ROE decreased compared to the previous year to 1.63 %, due to deterioration of net income.

More Return On Equity Ratios
Medical Equipment & Supplies Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
TFX's' Return on Equity at Yahoo Finance
TFX's Roe Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Roe for TFX's Competitors
Return On Equity for Teleflex Incorporated's Suppliers
Roe for TFX's Customers

Companies with similar Return On Equity at Jun 29 2025, within Healthcare Sector	ROE
Pfizer Inc	11.97 %
Hologic Inc	11.84 %
Pacific Health Care Organization Inc	11.75 %
Progyny Inc	11.55 %
Avantor Inc	11.51 %
Biomarin Pharmaceutical Inc	11.48 %
Conmed Corporation	11.37 %
Cormedix Inc	11.35 %
Boston Scientific Corporation	11.35 %
Align Technology inc	11.29 %
National Healthcare Corp	10.50 %
Select Medical Holdings Corp	10.50 %
U S Physical Therapy Inc	10.33 %
Monte Rosa Therapeutics Inc	9.95 %
Henry Schein Inc	9.92 %
Utah Medical Products Inc	9.92 %
Steris Plc	9.74 %
Medtronic Plc	9.63 %
Labcorp Holdings Inc	9.27 %
Infusystem Holdings Inc	9.11 %
Biogen Inc	9.04 %
Nature s Sunshine Products inc	8.75 %
Globus Medical Inc	8.58 %
Merit Medical Systems Inc	8.48 %
Addus Homecare Corp	8.43 %
Gyre Therapeutics Inc	8.11 %
Inspire Medical Systems inc	7.87 %
Tactile Systems Technology Inc	7.33 %
Theravance Biopharma inc	6.93 %
Elanco Animal Health Incorporated	6.74 %

Date modified: 2025-08-01T08:15:37+00:00

Help

About us

Terms of Use

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.